Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) – A systematic review, meta-analysis, and meta-regression. Issue 3 (May 2021)

• Record Type: Journal Article
• Authors: Rakhmat, Iis Inayati; Kusmala, Yudith Yunia; Handayani, Dewi Ratih; Juliastuti, Henny; Nawangsih, Eka Noneng; Wibowo, Arief; Lim, Michael Anthonius; Pranata, Raymond
• Is Part Of: Diabetes & metabolic syndrome. Volume 15:Issue 3(2021)
• Page Start: 777
• Page End: 782
• Publication Date: 2021-05
• Subjects: COVID-19 -- Diabetes -- Dipeptidyl peptidase-4 inhibitor -- SARS-CoV-2 -- Mortality; Diabetes -- Periodicals; Metabolism -- Disorders -- Periodicals; Diabetes Mellitus -- Periodicals; Metabolic Diseases -- Periodicals; Diabète -- Périodiques; Métabolisme, Troubles du -- Périodiques; Endocrinologie -- Périodiques; Diabète -- Physiopathologie -- Périodiques; Diabetes; Metabolism -- Disorders; Electronic journals; Periodicals; 616.462
• DOI: 10.1016/j.dsx.2021.03.027
• Languages: English
• ISSNs: 1871-4021

Abstract

Abstract: Background and aims: This study aims to synthesize evidence on dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in COVID-19 patients and factors affecting it. Methods: We performed a systematic literature search from PubMed, Scopus, and Embase databases from inception of databases up until 7 March 2021. Studies that met all of the following criteria were included: 1) observational studies or randomized controlled trials that report COVID-19 patients, 2) reporting DPP-4 inhibitor use, 3) mortality, and 4) mortality based on DPP-4 inhibitor use. The exposure was DPP-4 inhibitor, defined as DPP-4 inhibitor use that started prior to COVID-19 hospitalization. The control group was patients with no exposure to DPP-4 inhibitor. The outcome was mortality. The pooled effect estimate was reported as risk ratio (RR). Results: There were 4, 477 patients from 9 studies in this systematic review and meta-analysis. 31% of (15%, 46%) the patients use DPP-4 inhibitor. Mortality occurs in 23% (15%, 31%) of the patients. DPP-4 inhibitor was associated with lower mortality in patients with COVID-19 (RR 0.76 [0.60, 0.97], p = 0.030, I2: 44.5%, p = 0.072). Meta-regression analysis showed that the association between DPP-4 inhibitor and mortality was significantly affected by metformin (RR 1.02 [1.00, 1.04], p = 0.048) and angiotensin converting enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB) use (RR 1.04 [1.01, 1.07], p = 0.006), but not age (p = 0.759), sex (reference: male, p = 0.148), and hypertension (p = 0.218). Conclusion: DPP-4 inhibitor use was associated with lower mortality in COVID-19 patients, and the association was weaker in patients who were also taking metformin and/or ACE inhibitors. Highlights: DPP-4 inhibitor use was associated with lower mortality in patients with COVID-19 (RR 0.76). The association was weaker in patients who were also taking metformin and/or ACE inhibitors. The evidence supports continuation of DPP4 inhibitors in patients with COVID-19.